Erasca, Inc.
ERAS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761918
No open-market purchases or sales by Erasca, Inc. insiders were filed in the last 90 days; 256 institutions reported holding it in 13F filings for Q2 2026, worth $5.13B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $5.41B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +34 vs. previous quarter
- 256
- 13F valueReported value at the end of Q2 2026
- $5.13B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$124.5M
- No comparable prior period
- Free cash flow, FY2025
- -$95.6M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 37.2M
- Shares sold short
- Change
- +193.2K
- +0.5% vs. previous
- Days to cover
- 8.89
- At average daily volume
Superinvestors holding ERAS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ERAS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Erasca, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Garner EbunChief Legal Officer | SSale | −80.0K | $16.40 | −$1.31M | −76.1%25.1K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Morris ShannonChief Medical Officer | SSale | −20.0K | $15.04 | −$300.8K | −100.0%0 after | 10b5-1 |
| Jan 8, 2026 (view filing) | Jan 7 | 1 day | Garner EbunGeneral Counsel & Corp. Sec. | SSale | −120.0K | $5.59 | −$670.8K | −82.7%25.1K after | 10b5-1 |
| May 22, 2024 (view filing) | May 21 | 1 day | Casdin Alexander W.Director | PPurchase | +80.0K | $2.27 | +$181.6K | +16.2%574.0K after | |
| Dec 8, 2023 (view filing) | Dec 6 | 2 days | Start Valerie Denise HardingDirector | PPurchase | +10.0K | $1.85 | +$18.5K | +100.0%20.0K after | |
| Dec 6, 2023 (view filing) | Dec 5-6 | 1 day | Lim Jonathan EChairman & CEO | PPurchase | +1.00M | $1.70 | +$1.70M | +8.4%12.9M after | 2 lots |
| Dec 4, 2023 (view filing) | Dec 4 | Same day | Casdin Alexander W.Director | PPurchase | +30.0K | $1.66 | +$49.8K | +6.5%494.0K after | |
| Oct 10, 2023 (view filing) | Oct 5 | 5 days | Lim Jonathan EChairman & CEO | PPurchase | +1.00M | $2.03 | +$2.03M | +5.4%19.5M after | |
| Jun 8, 2023 (view filing) | Jun 8 | Same day | Lim Jonathan EChairman & CEO | PPurchase | +100.0K | $2.75 | +$275.0K | +0.5%18.4M after | |
| Apr 11, 2023 (view filing) | Apr 10 | 1 day | Casdin Alexander W.Director | PPurchase | +20.0K | $2.76 | +$55.2K | +4.5%464.0K after |
Top 10 13F holders, Q2 2026
See all 256 holdersThe largest institutional positions in Erasca, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | $457.5M | 9.96% | +300,000+1.2% | Added |
| T. Rowe Price Investment Management, Inc. | 21,185,839 | $388.1M | 0.25% | −73,807−0.3% | Reduced |
| BlackRock, Inc. | 21,154,146 | $387.5M | 0.01% | +1,002,740+5.0% | Added |
| RTW Investments, LP | 17,946,754 | $328.8M | 2.81% | +1,789,579+11.1% | Added |
| VR Adviser, LLC | 17,891,812 | $327.8M | 9.94% | +1,509,000+9.2% | Added |
| State Street Corp | 12,184,555 | $223.2M | 0.01% | +2,884,471+31.0% | Added |
| Logos Global Management LP | 12,150,000 | $222.6M | 9.58% | +1,000,000+9.0% | Added |
| Vanguard Capital Management LLC | 11,402,199 | $208.9M | 0.00% | +152,461+1.4% | Added |
| Siren, L.L.C. | 11,397,781 | $208.8M | 4.24% | +153,535+1.4% | Added |
| Paradigm Biocapital Advisors LP | 9,550,000 | $175.0M | 3.28% | −842,702−8.1% | Reduced |
Holders of 5% or more of ERAS
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Erasca, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| City Hill, LLC | 13G/A | 10.40%37.0M shares | – | Feb 14, 20225 filings | Aug 14, 2026 | SEC |
| T. Rowe Price Investment Management, Inc. | 13G/A | 6.80%21.2M shares | +1.10 ppfrom 5.70% | Nov 14, 20244 filings | May 15, 2026 | SEC |
| Venrock Healthcare Capital Partners III, L.P. | 13G/A | 5.30%16.4M shares | – | May 31, 20242 filings | May 15, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.30%15.0M shares | −2.70 ppfrom 8.00% | May 29, 20243 filings | Aug 14, 2025 | SEC |
| RTW Investments, LP | 13G | 5.20%16.2M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |